Home > Insider Trading > Filing (0001595585-19-000278)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1595585	Tricida Inc.	TCDA	Pharmaceutical Preparations (2834)	463372526

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1743664	J Edward Hejlek	7000 Shoreline Court, Suite 201 South San Francisco CA 94080	Svp, General Counsel & Secy.	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-12-20	15,000	$0.96	29,882	No	4	M	Direct
Common Stock	Disposition	2019-12-20	15,000	$38.17	14,882	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2019-12-20	15,000	$0.00	15,000	$0.96

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
138,343		2026-02-23	No	4	M	Direct

Footnotes

This amount includes 774 shares acquired on December 31, 2018 and 950 shares acquired on June 28, 2019 under the Tricida, Inc. 2018 Employee Stock Purchase Plan. These acquisitions are exempt from Section 16(b) pursuant to Rule 16b-3(c) and exempt from Section 16(a) pursuant to Rule 16a-3(f)(1)(i)(B).
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.78 to $38.72, inclusive. The reporting person undertakes to provide to Tricida, Inc., any security holder of Tricida, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
This option vested 25% on January 1, 2017, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the issuer's right of repurchase.